{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:33:50Z","timestamp":1776274430400,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.vaccine.2018.04.038","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T07:51:56Z","timestamp":1528444316000},"page":"4369-4374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012\u20132016"],"prefix":"10.1016","volume":"36","author":[{"given":"William L.","family":"Walker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"Hills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine R.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid B.","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.04.038_b0005","series-title":"CDC Yellow Book 2018 health information for international travel","first-page":"214","article-title":"Japanese Encephalitis","author":"Hills","year":"2017"},{"key":"10.1016\/j.vaccine.2018.04.038_b0010","series-title":"Emerging Infections 8","first-page":"93","article-title":"Japanese encephalitis prevention and control: advances, challenges, and new initiatives","author":"Fischer","year":"2008"},{"key":"10.1016\/j.vaccine.2018.04.038_b0015","doi-asserted-by":"crossref","first-page":"930","DOI":"10.4269\/ajtmh.2010.09-0676","article-title":"Japanese encephalitis in travelers from non-endemic countries, 1973\u20132008","volume":"82","author":"Hills","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.04.038_b0020","first-page":"1","article-title":"Japanese encephalitis vaccines: recommendations of the advisory committee on immunization practices (ACIP)","volume":"59","author":"Fischer","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2018.04.038_b0025","first-page":"898","article-title":"Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.04.038_b0030","unstructured":"Food and Drug Administration. Ixiaro \u2014 Summary Basis for Regulatory Action. Available at: http:\/\/wayback.archive-it.org\/7993\/20170723030915\/https:\/\/www.fda.gov\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm142580.htm [accessed 02 January 2018]."},{"key":"10.1016\/j.vaccine.2018.04.038_b0035","first-page":"661","article-title":"Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.04.038_b0040","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1016\/j.vaccine.2010.07.040","article-title":"Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up","volume":"28","author":"Dubischar-Kastner","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.038_b0045","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1086\/590116","article-title":"Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine","volume":"198","author":"Tauber","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.038_b0050","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.vaccine.2009.10.024","article-title":"Immunogenicity and safety of IXIARO (IC51) in a phase II study in healthy Indian children between 1 and 3 years of age","volume":"28","author":"Kaltenbock","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.038_b0055","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/INF.0000000000001623","article-title":"Safety of the inactivated Japanese encephalitis virus vaccine IXIARO in children: An open-label, randomized, active-controlled, phase 3 study","volume":"36","author":"Dubischar","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.04.038_b0060","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1016\/j.vaccine.2016.07.029","article-title":"Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO in elderly subjects: open-label, uncontrolled, multi-center, phase 4 study","volume":"34","author":"Cramer","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.038_b0065","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.vaccine.2014.11.046","article-title":"Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009\u20132012","volume":"33","author":"Rabe","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.038_b0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vaccine.2010.10.016","article-title":"Adverse event reports following Japanese encephalitis vaccination in the United States, 1999\u20132009","volume":"29","author":"Lindsey","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.038_b0075","first-page":"149","article-title":"Tolerability of Japanese encephalitis vaccine in pediatric patients","volume":"6","author":"Butler","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2018.04.038_b0080","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.038_b0085","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the vaccine adverse event reporting system","volume":"23","author":"Varricchio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.04.038_b0090","unstructured":"Food and Drug Administration. Code of Federal Regulations Title 21, Sec. 600.80 Postmarketing reporting of adverse experiences, 2017. Available at: http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=600.80 [accessed 28 December 2017]."},{"key":"10.1016\/j.vaccine.2018.04.038_b0095","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.038_b0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.vaccine.2003.09.008","article-title":"Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation","volume":"22","author":"Bonhoeffer","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.038_b0105","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1016\/j.vaccine.2007.04.060","article-title":"Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Sejvar","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.038_b0110","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.038_b0115","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.vaccine.2007.04.058","article-title":"Aseptic meningitis: Case definition and guidelines for collection, analysis and presentation of immunization safety data","volume":"25","author":"Tapiainen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.038_b0120","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/S0264-410X(00)00111-0","article-title":"Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group","volume":"18","author":"Takahashi","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.038_b0125","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.vaccine.2009.10.024","article-title":"Immunogenicity and safety of Ixiaro (IC51) in a phase II study in healthy Indian children between 1 and 3 years of age","volume":"28","author":"Kaltenb\u00f6ck","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.038_b0130","unstructured":"Food and Drug Administration. BioThrax (Anthrax Vaccine Adsorbed) product approval information [package insert]. Available at: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/UCM074923.pdf [accessed 28 December 2017]."},{"key":"10.1016\/j.vaccine.2018.04.038_b0135","unstructured":"Food and Drug Administration. ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) product approval information [package insert]. Available at: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM142572.pdf [accessed 28 December 2017]."},{"key":"10.1016\/j.vaccine.2018.04.038_b0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0264-410X(96)00170-3","article-title":"Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines","volume":"15","author":"Sakaguchi","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.038_b0145","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The Vaccine Adverse Event Reporting System (VAERS)","volume":"12","author":"Chen","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.038_b0150","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2105\/AJPH.85.12.1706","article-title":"The reporting sensitivities of two passive surveillance systems for vaccine adverse events","volume":"85","author":"Rosenthal","year":"1995","journal-title":"Am J Public Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:27:57Z","timestamp":1759400877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18305218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":30,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0264410X18305218"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.038","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012\u20132016","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}